title: Design of an isolated pig heart preparation for positron emission tomography and magnetic resonance imaging.
abstract: OBJECTIVE
  Validation of new positron emission tomography (PET) tracers or magnetic (MR) imaging contrast agents is based on isolated rodent heart preparations. The use of larger animals could provide a more direct validation using the devices used for humans.
  
  
  METHODS
  An isolated pig heart preparation has been developed and adapted to the technical constraints of whole body PET and MR imaging. This preparation could be used either in the Langendorff or working mode after selective cannulation of both coronary arteries.
  
  
  RESULTS
  The authors showed that quantification of regional kinetics of PET tracers was possible using this preparation by measuring fluorine-18-labeled deoxyglycose (18FDG) kinetics in remote and ischemic territories. Experiments using MR imaging contrast agents, for myocardial perfusion, demonstrated the ability of this preparation to accurately validate these contrast agents over a wide range of flow rates.
  
  
  CONCLUSIONS
  An isolated pig heart preparation could be developed to fulfill the constraints of PET and MR imaging, and proved useful for the study of the distribution of different tracers or contrast media developed for functional cardiac imaging in humans.
authors.affiliation: Centre d'Explorations et de Recherche Médicales par Emission de Positons (CERMEP), Lyon, France.
authors.forename: C
authors.initials: C
authors.lastname: Casali
authors.forename: J F
authors.initials: JF
authors.lastname: Obadia
authors.forename: E
authors.initials: E
authors.lastname: Canet
authors.forename: K
authors.initials: K
authors.lastname: Bendjelid
authors.forename: X
authors.initials: X
authors.lastname: André-Fouët
authors.forename: D
authors.initials: D
authors.lastname: Revel
authors.forename: M F
authors.initials: MF
authors.lastname: Janier
mesh_terms: D000818:Animals; D002614:Chelating Agents / Q000493:pharmacokinetics; D003287:Contrast Media / Q000493:pharmacokinetics; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006321:Heart / Q000000981:diagnostic imaging*; D006571:Heterocyclic Compounds / Q000493:pharmacokinetics; D007091:Image Processing, Computer-Assisted; D066298:In Vitro Techniques; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D009929:Organ Size; D009942:Organometallic Compounds / Q000493:pharmacokinetics; D010477:Perfusion / Q000379:methods; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012107:Research Design; D013552:Swine; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D002614:Chelating Agents; D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C107329:carboxymethyl-dextran-A2-gadolinium-DOTA; D019788:Fluorodeoxyglucose F18; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate